The U.S. Food and Drug Administration (FDA) has approved Lupin Limited’s generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). Like the name-brand medicine sold by Sunovion Pharmaceuticals, the new generic is indicated for long-term maintenance treatment, according to…
A Phase 2 trial designed to test a self-administered inhaled formulation of nitric oxide (NO) for adults with chronic obstructive pulmonary disease (COPD), or bronchiectasis, is recruiting eligible patients. The formulation, called RESP301, is a liquid solution that, once inhaled through a nebulizer, releases NO into the lungs. RESP301 was…
Abnormally high levels of iron inside airway immune cells are associated with more frequent lung infection-related exacerbations in people with chronic obstructive pulmonary disease (COPD), a study shows. Excess iron was also shown to impair the ability of these cells, called macrophages, to fight COPD-related microbes, and can be used…
A team of researchers have created a comprehensive blueprint of cells that are in the lungs of chronic obstructive pulmonary disease (COPD) patients, which helped them identify previously unknown cell subpopulations and changes in gene activity and cellular interactions. “Our analysis identified novel changes in gene expression [activity] and…
Animal and human studies highlight the potential of nomacopan, an investigational inhaled medicine to alleviate severe exacerbations caused by inflammatory lung diseases, such as chronic obstructive pulmonary disease (COPD). Akari Therapeutics, the company developing the therapy, is collaborating with Inhalation Sciences to refine the dosing and pharmacological…
Verona Pharma has completed patient enrollment for ENHANCE-2, a Phase 3 clinical trial evaluating the safety and efficacy of ensifentrine, an inhalation therapy for chronic obstructive pulmonary disease (COPD). According to Verona, the trial exceeded its enrollment target of 800 participants, even amid the COVID-19 pandemic. Top-line data are…
Researchers have discovered that an ion channel protein called TRPML3 may be a new therapeutic target for chronic obstructive pulmonary disease (COPD). Their preclinical study found that the protein regulates the levels of MMP-12, a molecule produced in lung immune cells and known to drive COPD. Mice lacking the…
Patients in the U.S. with chronic obstructive pulmonary disease (COPD) or other respiratory conditions may now have their own AirPhysio device from Life Wellness Healthcare delivered to their homes, thanks to an update the company made to its online store. This update will allow patients to order the…
Standardized questionnaires can effectively be used to help diagnose chronic obstructive pulmonary disease (COPD) in settings where healthcare resources may be limited, according to a new study. The study, “Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings,” was…
A first patient has been enrolled in a Phase 4 study of the effectiveness of Yupelri (revefenacin) against Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The respective safety of these two approved, once-daily COPD maintenance treatments will also be evaluated. Yupelri, developed…
Get regular updates to your inbox.